Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families

Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families

Dezembro 05, 2017

Invitae to present findings at 2017 San Antonio Breast Cancer Symposium

Research presented today by Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, shows how clinicians are using genetic testing beyond BRCA1 and BRCA2 to guide treatment and screening decisions for hereditary breast and ovarian cancer (HBOC) patients and their families. The data are being presented at the 2017 San Antonio Breast Cancer Symposium.

Earlier research from Invitae published in the October issue of Annals of ...

Read more


Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services

Novembro 15, 2017

Complements recent acquisition of Good Start Genetics to establish comprehensive service for IVF clinics, ob/gyns

Entry into family health genetics creates integrated platform to support use of genetics in mainstream medical care

Results of warrant exchange offer announced

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has completed its acquisition of CombiMatrix, which specializes in providing genetic information for prenatal diagnosis, miscarriage analysis and diagnosis of pediatric developmental disorders, establishing Invitae as ...

Read more


Invitae Corporation Issues Reminder Regarding Exchange Offer for CombiMatrix Corporation Series F Warrants

Invitae Corporation Issues Reminder Regarding Exchange Offer for CombiMatrix Corporation Series F Warrants

Novembro 08, 2017

Exchange Offer to Expire One Minute After 11:59 p.m., New York City Time, on November 13, 2017, Unless Extended

Invitae Corporation (NYSE: NVTA) one of the fastest growing genetic information companies, today issued a reminder to CombiMatrix Corporation Series F warrant holders regarding the previously announced offer to exchange (the “Exchange Offer”) each outstanding Series F warrant (CUSIP No. 20009T147) (the “CombiMatrix Series F warrants”) to acquire one share of common stock of CombiMatrix Corporation (“CombiMatrix”) for 0 ...

Read more


Invitae Reports Double-Digit Sequential Volume and Revenue Growth  in Third Quarter 2017

Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017

Novembro 06, 2017

Momentum in base business complemented by strategic expansion into family health genetics

Hosting conference call today at 4:30 pm ET / 1:30 pm PT

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended September 30, 2017, including continued business momentum, double-digit sequential volume and revenue growth, and a strengthened financial position.

Third Quarter 2017 Operational Highlights

  • Strategic expansion into reproductive health creates comprehensive platform offering genetic ...

Read more


Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of Miscarriage

Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of Miscarriage

Outubro 30, 2017

Research showing re-biopsy may help preserve healthy embryos also presented at the American Society for Reproductive Medicine 2017 Scientific Congress & Expo

Invitae (NYSE: NVTA), one of the fastest growing genetic information companies, is presenting validation data for a novel, NGS-based preimplantation genetic screening (PGS) technology that accurately identifies certain chromosomal abnormalities potentially missed on other PGS platforms. In addition, company researchers are sharing data suggesting that if initial PGS testing yields no results, a second biopsy may provide actionable ...

Read more


Invitae to announce third quarter 2017 Financial Results and Host Conference Call on November 6, 2017

Invitae to announce third quarter 2017 Financial Results and Host Conference Call on November 6, 2017

Outubro 24, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its third quarter 2017 financial results on Monday, November 6, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (844) 579-6824 for domestic callers and (763) 488-9145 for international callers, and the reservation number for ...

Read more


Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection

Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection

Outubro 17, 2017

Presentation at the American Society of Human Genetics Annual Meeting also highlights use of virtual panels to identify clinically important secondary findings

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, is presenting data showing genetic sequencing and copy number variant (CNV) detection performed together using expert-curated panels offers better diagnosis rates over sequencing alone in patients with neuromuscular disorders and childhood epilepsy. The studies are among the company’s 15 posters and presentations at the 2017 American ...

Read more


Invitae Commences Exchange Offer for CombiMatrix Series F Warrants

Invitae Commences Exchange Offer for CombiMatrix Series F Warrants

Outubro 06, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it has commenced an offer to exchange (the “Exchange Offer”) each outstanding Series F warrant (CUSIP No. 20009T147) (the “CombiMatrix Series F Warrants”) to acquire one share of common stock of CombiMatrix Corporation (“CombiMatrix”) for 0.3056 of a share of common stock, par value $0.0001 per share, of Invitae (the “Invitae Common Stock”).

Upon the terms and subject to the conditions set forth ...

Read more


Invitae’s new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide

Invitae’s new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide

Outubro 05, 2017

Refinements to existing guidelines establish a more detailed and transparent approach for classifying variants at scale

As genetic testing grows both more complex and more integrated into mainstream medical care, continually improving how genetic variants are classified as pathogenic, benign or unknown is essential. Researchers with Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, have developed and validated a new framework that refines genetic variant classification guidelines, resulting in a more complete and consistent approach that ...

Read more


Invitae Highlighting New Research, Expanded Suite of Services at National Society of Genetic Counselors (NSGC) 36th Annual Conference

Invitae Highlighting New Research, Expanded Suite of Services at National Society of Genetic Counselors (NSGC) 36th Annual Conference

Setembro 13, 2017

Research highlights utility of proactive genetic screening in healthy adults

Award-winning genetic information tool added to support use of genetic information as part of mainstream medical care throughout life

Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present initial findings showing proactive genetic health screening revealed medically significant findings for nearly one in five patients in a study presented at the National Society of Genetic Counselors (NSGC) 36th Annual Conference. The company will ...

Read more